Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Biofrontera Initiated with a Buy at Roth Capital, Stock Surges

Published 11/24/2021, 09:54 AM
Updated 11/24/2021, 09:56 AM
© Reuters.

By Sam Boughedda

Investing.com — Biopharmaceutical firm Biofrontera Inc (NASDAQ:BFRI) has seen its share price jump 135% to $6.19 in Wednesday trading after analysts at Roth Capital initiated the stock with a buy rating.

The stock, which made its public debut on October 28, had been steadily declining since touching an intraday high of $4.99 at the start of November.

Roth analyst Jonathan Aschoff set a 12-month price target of $20 for the shares, saying they project future U.S. revenue from the Ameluz and Xepi treatments in actinic keratosis and impetigo, respectively. 

"Our initial valuation excludes potential commercial upside from any potential future programs, given BFRI’s clear focus on its two currently approved drugs," Aschoff said. 

On Tuesday, Biofrontera announced that it will release its third-quarter results on November 30.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.